Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA7 | P43166 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 6/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | FABP3 | P05413 | 1/20 | 0.47 |
| ▸ | FABP4 | P15090 | 1/20 | 0.47 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.46 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL668753 | 0.98 | HTT (0.53) | HTTCA12CA1CA2CA7 | |
| SCHEMBL8482147 | 0.86 | HTT (0.54) | HTTCA12CA1CA2CA7 | |
| SCHEMBL14864224 | 0.86 | LMNA (0.53) | HTTCA12CA1CA2CA7 | |
| SCHEMBL1987451 | 0.86 | HTT (0.54) | HTTCA12CA1CA2CA7 | |
| SCHEMBL11790880 | 0.84 | HTT (0.53) | HTTCA12CA1CA2CA7 | |
| SCHEMBL2315524 | 0.84 | HTT (0.53) | HTTCA12CA1CA2CA7 | |
| SCHEMBL668359 | 0.84 | HTT (0.53) | HTTCA12CA1CA2CA7 | |
| SCHEMBL2427873 | 0.83 | HTT (0.56) | HTTCA12CA1CA2CA7 | |
| SCHEMBL668752 | 0.83 | CTSD (0.44) | HTTCA12CA1CA2CA7 | |
| SCHEMBL667788 | 0.81 | HTT (0.50) | HTTCA12CA1CA2CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1601642-B1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-1601642-B1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2017-01-04 | — | — | EP | disclosed |
| EP-2463269-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| EP-2463269-B1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORP (US) | 2016-09-28 | — | — | EP | disclosed |
| US-9359289-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359289-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-9359289-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-06-07 | — | — | US | disclosed |
| US-20160039750-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | INTREXON CORPORATION (US) | 2016-02-11 | — | — | US | disclosed |
| US-9255273-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-02-09 | — | — | US | disclosed |
| US-9255273-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-02-09 | — | — | US | disclosed |
| US-7456315-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-7456315-B2 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2008-11-25 | — | — | US | disclosed |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE, INC. | 2008-03-13 | — | — | US | disclosed |
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | RHEOGENE, INC. | 2006-01-26 | — | — | US | disclosed |
| EP-1053269-B1 | METHOD FOR PRODUCING SOFT AND ELASTIC, SEMI-HARD OR HARD MOULDED BODIES OF POLYURETHANE FREE FROM FLUOROCHLOROHYDROCARBON AND HAVING A CELLULAR CORE AS WELL AS A COMPACTED SIDE AREA | BASF AG (DE) | 2003-04-02 | — | — | EP | disclosed |
| EP-1053269-A1 | METHOD FOR PRODUCING SOFT AND ELASTIC, SEMI-HARD OR HARD MOULDED BODIES OF POLYURETHANE FREE FROM FLUOROCHLOROHYDROCARBON AND HAVING A CELLULAR CORE AS WELL AS A COMPACTED SIDE AREA | BASF AKTIENGESELLSCHAFT (DE) | 2000-11-22 | — | — | EP | disclosed |
| WO-1999040138-A1 | METHOD FOR PRODUCING SOFT AND ELASTIC, SEMI-HARD OR HARD MOULDED BODIES OF POLYURETHANE FREE FROM FLUOROCHLOROHYDROCARBON AND HAVING A CELLULAR CORE AS WELL AS A COMPACTED SIDE AREA | BASF AKTIENGESELLSCHAFT (DE) | 1999-08-12 | — | — | WO | disclosed |
| US-5856334-A | ANTAGONIST FOR EOSINOPHILS | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1999-01-05 | — | — | US | disclosed |
| EP-0773219-A1 | IMIDAZOQUINOLINE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064741-A1 | BIOAVAILABLE DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES VIA AN ECDYSONE RECEPTOR COMPLEX | NR2E3, NR5A1, NR5A2 | HTT 4667/4885CA12 4072/4885CA1 4351/4885 |
| US-20060020146-A1 | Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex | NR2E3, NR5A1, NR5A2 | HTT 4667/4885CA12 4072/4885CA1 4351/4885 |
| US-20160039750-A1 | Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex | NR2E3, NR5A1, NR5A2 | HTT 4667/4885CA12 4072/4885CA1 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.